Pyxis Oncology, Inc. filings document a clinical-stage oncology company developing MICVO, an investigational antibody-drug conjugate for difficult-to-treat cancers. Its 8-K reports cover financial results, corporate updates, Regulation FD presentations, clinical data disclosures, and trial-related updates for MICVO in recurrent or metastatic head and neck squamous cell carcinoma and other advanced solid tumors.
The company’s regulatory record also includes proxy materials for annual meeting matters, director elections, governance proposals, executive transitions, employment and separation arrangements, equity compensation matters, and emerging growth company status. These filings describe Pyxis Oncology’s public-company governance, program disclosures, capital-related arrangements, and risk-linked clinical development reporting.
Pyxis Oncology, Inc. reported a net loss of $25.3 million for the quarter and $48.6 million for the six months ended June 30 2026, with an accumulated deficit of $491.8 million. Cash, cash equivalents and marketable debt securities totaled $33.0 million at quarter end, and management stated there is substantial doubt about the company’s ability to continue as a going concern over the next year without additional financing.
Subsequent to quarter end, Pyxis closed a private placement raising gross proceeds of approximately $50 million and issued common warrants that could provide up to about $64 million more if exercised for cash, which together are expected to fund operations into the second quarter of 2027. The company remains a clinical‑stage oncology business focused on its lead antibody‑drug conjugate MICVO for recurrent and metastatic head and neck squamous cell carcinoma, with ongoing Phase 1 monotherapy and combination studies showing encouraging objective response and disease control rates in heavily pre‑treated patients.
Pyxis Oncology, Inc. reported second quarter 2026 results and detailed progress for its lead antibody-drug conjugate, micvotabart pelidotin (MICVO), in recurrent/metastatic head and neck squamous cell carcinoma. For the quarter ended June 30, 2026, the company recorded a net loss of $25.3 million, or ($0.40) per share, compared with a net loss of $18.4 million, or ($0.30) per share, a year earlier, driven mainly by higher general and administrative expenses.
Research and development expenses were $16.1 million versus $17.1 million in the prior-year quarter, while general and administrative expenses increased to $9.9 million from $5.4 million, largely due to severance and stock-based compensation. As of June 30, 2026, cash, cash equivalents, restricted cash and short-term investments totaled $34.5 million.
The company completed a private placement of up to $114 million, providing approximately $50 million in upfront gross proceeds (of which $10.0 million was received by June 30, 2026) and extending its cash runway into the second quarter of 2027. Updated MICVO monotherapy data in 2L+ R/M HNSCC are expected in Fall 2026, with updated first-line combination data with KEYTRUDA in the fourth quarter of 2026. MICVO holds U.S. FDA Fast Track Designation in R/M HNSCC.
GordonMD Global Investments LP and related entities filed an initial ownership report for Pyxis Oncology, Inc.. Through GordonMD Long Biased Master Fund LP, they report indirect holdings of 10,024,909 shares of common stock. They also report a Common Stock Purchase Warrant directly held for up to 4,900,039 underlying shares at an exercise price of $3.289 per share, expiring on July 2, 2029. The warrant becomes exercisable on the earlier of the Issuer’s first public disclosure of clinical data from its MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC or October 1, 2026. The Master Fund, its general partner, and Craig D. Gordon each disclaim beneficial ownership beyond any pecuniary interest.
Pyxis Oncology, Inc. has a significant shareholder group led by Biotechnology Value Fund entities and Mark N. Lampert. As of the close of business on July 10, 2026, these reporting persons and a managed account held an aggregate of 7,840,062 Warrants exercisable for 7,840,062 shares of common stock at an exercise price of $3.289 per share, expiring on July 2, 2029. A 9.99% beneficial ownership limitation caps immediate exercisability to 496,840 of these shares. Based on an adjusted share-count denominator that includes previously outstanding shares, shares issued under a June 30, 2026 Securities Purchase Agreement, and the 496,840 issuable shares, BVF beneficially owned 4,611,887 shares (approximately 5.5% of the class), BVF II 3,083,847 shares (approximately 3.7%), and the trading fund 518,280 shares (less than 1%). Through layered general partner and investment manager relationships, BVF Partners L.P., BVF Inc., and Mr. Lampert may each be deemed to beneficially own approximately 9.99% of the outstanding shares, subject to the ownership cap, while various entities expressly disclaim beneficial ownership of securities held by affiliated funds.
Pyxis Oncology director Jakob Dupont reported an exercise-and-sale of company stock. He exercised stock options covering 35,000 shares of common stock at an exercise price of $1.60 per share and received the underlying shares.
On the same date, he sold 35,000 common shares in open-market transactions at a weighted average price of $3.06 per share, with trade prices ranging from $3.00 to $3.36. These sales were carried out under a pre-arranged Rule 10b5-1 trading plan. After the transactions, Dupont holds 38,741 shares of Pyxis Oncology common stock directly.
Pyxis Oncology, Inc. entered into definitive securities purchase agreements for a private placement of 19,600,153 shares of common stock at $2.551 per share, together with common warrants to purchase an equal number of shares at an exercise price of $3.289. The deal is expected to provide approximately $50 million in upfront gross proceeds and up to an additional $64 million if the warrants are exercised for cash. Management expects this funding to extend the company’s cash runway into the second quarter of 2027 and to support development of its lead cancer therapy MICVO through key Phase 1 and Phase 1/2 clinical milestones, with updated monotherapy data planned for Fall 2026 and combination data in the fourth quarter of 2026. Pyxis also granted investors registration rights to resell the shares and warrant shares.
Pyxis Oncology, Inc. ownership disclosure shows GordonMD-related reporting persons each beneficially hold 10,024,909 shares of Common Stock, representing 12.1% of the class as reported. The filing lists shared voting and dispositive power of 10,024,909 shares and includes standard disclaimers about beneficial ownership.
Pyxis Oncology, Inc. held its Annual Meeting of Stockholders in virtual format on June 15, 2026. As of the April 20, 2026 record date, 62,855,464 shares of common stock were outstanding and entitled to vote. A quorum was present, with 47,302,035 shares represented virtually, in person or by proxy.
Stockholders elected three Class II directors—Thomas Civik, Freda Lewis-Hall, M.D., and Michael A. Metzger—to serve until the 2029 annual meeting and until their successors are elected and qualified. Support levels varied by nominee, with for votes ranging from 19,188,755 to 27,341,415.
Stockholders also ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 46,203,257 votes for, 1,076,997 against and 21,781 abstentions.
Pyxis Oncology reported a net loss of $23.3 million for the quarter ended March 31, 2026, slightly higher than the $21.2 million loss a year earlier, as it increased spending on its lead cancer drug candidate MICVO.
Research and development expenses rose to $20.0 million, driven mainly by higher clinical trial and preclinical costs for MICVO monotherapy and combination studies. General and administrative expenses fell to $4.4 million, largely due to lower stock-based compensation.
Pyxis ended the quarter with $41.0 million in cash, cash equivalents and marketable debt securities and an accumulated deficit of $466.4 million. Management states there is substantial doubt about the company’s ability to continue as a going concern beyond the next 12 months without additional financing, despite having an effective $350.0 million shelf registration and $150.0 million at-the-market capacity.